|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
PLoS By Category | Recent
PLoS Articles
|
|
Biochemistry - Chemistry - Molecular Biology - Pharmacology - Respiratory Medicine
|
Efficacy of a Novel Class of RNA Interference Therapeutic Agents
Published:
Wednesday, August 15, 2012
Author:
Tomohiro Hamasaki et al.
by Tomohiro Hamasaki, Hiroshi Suzuki, Hisao Shirohzu, Takahiro Matsumoto, Corina N. D'Alessandro-Gabazza, Paloma Gil-Bernabe, Daniel Boveda-Ruiz, Masahiro Naito, Tetsu Kobayashi, Masaaki Toda, Takayuki Mizutani, Osamu Taguchi, John Morser, Yutaka Eguchi, Masahiko Kuroda, Takahiro Ochiya, Hirotake Hayashi, Esteban C. Gabazza, Tadaaki Ohgi
RNA interference (RNAi) is being widely used in functional gene research and is an important tool for drug discovery. However, canonical double-stranded short interfering RNAs are unstable and induce undesirable adverse effects, and thus there is no currently RNAi-based therapy in the clinic. We have developed a novel class of RNAi agents, and evaluated their effectiveness in vitro and in mouse models of acute lung injury (ALI) and pulmonary fibrosis. The novel class of RNAi agents (nkRNA®, PnkRNA™) were synthesized on solid phase as single-stranded RNAs that, following synthesis, self-anneal into a unique helical structure containing a central stem and two loops. They are resistant to degradation and suppress their target genes. nkRNA and PnkRNA directed against TGF-ß1mRNA ameliorate outcomes and induce no off-target effects in three animal models of lung disease. The results of this study support the pathological relevance of TGF-ß1 in lung diseases, and suggest the potential usefulness of these novel RNAi agents for therapeutic application.
More...
|
|
|
 |
|
|
|
|
|
|
|
|